Impact of previous insulin therapy on the prognosis of diabetic patients with acute coronary syndromes

Cardiology Department, Coimbra University Hospital, Portugal.
Arquivos brasileiros de endocrinologia e metabologia (Impact Factor: 0.84). 10/2010; 54(7):612-9. DOI: 10.1590/S0004-27302010000700005
Source: PubMed


To determine whether previous insulin treatment independently influences subsequent outcomes in diabetic patients with ACS (acute coronary syndromes).
375 diabetic patients with ACS, divided in 2 groups: Group A (n = 69)--previous insulin and Group B (n = 306)--without previous insulin. Predictors of 1-year mortality and major adverse cardiac events (MACE) were analyzed by Cox regression analysis.
Group A had more previous stroke (17.4% vs. 9.2%, p = 0.047) and peripheral artery disease (13.0% vs. 3.6%, p = 0.005). They had significantly higher admission glycemia and lower LDL cholesterol. There were no significant differences in the type of ACS, in 1-year mortality (18.2% vs. 10.4%, p = 0.103) or MACE (32.1% vs. 23.0%, p = 0.146) between groups. In multivariate analysis, insulin treatment was neither an independent predictor of 1-year mortality nor of MACE.
Despite the more advanced atherosclerotic disease, diabetics under insulin had similar outcomes to those without insulin. Insulin may protect diabetics from the expected poor adverse outcome of an advanced atherosclerotic disease.

Download full-text


Available from: Lino Gonçalves, Mar 11, 2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: Patients with diabetes mellitus (DM) presenting with acute myocardial infarction (AMI) have worse outcomes versus those without DM. Comparative contemporary data in patients presenting with AMI with insulin-requiring diabetes mellitus (IRDM), noninsulin-requiring diabetes mellitus (NIRDM), and newly identified DM (hemoglobin A1C level >6.5%) versus patients without DM are limited. This observational study from the National Cardiovascular Data Registry (NCDR) Acute Coronary Treatment and Intervention Outcomes Network-Get with the Guidelines (ACTION Registry-GWTG consisted of 243,861 patients with AMI from 462 US sites identified from January 2007 to March 2011 entered into the registry. Clinical characteristics, management, and in-hospital outcomes were analyzed. Patients with DM with non-ST-segment elevation myocardial infarction (NSTEMI; n = 53,094, 35%) were less likely to undergo diagnostic angiography or revascularization, whereas those with ST-segment elevation myocardial infarction (STEMI) (n = 21,507, 23%) were less likely to undergo reperfusion therapy compared with patients without DM. There was an increased adjusted risk of in-hospital mortality in the DM group in both the NSTEMI (odds ratio [OR] 1.14, 95% confidence interval [CI] 1.06 to 1.22) and STEMI (OR 1.17, 95% CI 1.07 to 1.27) population. In patients with DM, the risk-adjusted in-hospital mortality was higher in patients with IRDM than those with NIRDM in the NSTEMI group (OR 1.12, 95% CI 1.01 to 1.24) but not in the STEMI group (OR 1.12, 95% CI 0.95 to 1.32). Newly diagnosed patients with DM presenting with AMI had similar unadjusted in-hospital outcomes compared with patients without DM. In conclusion, patients with DM presenting with AMI have a higher mortality risk than patients without DM. In patients with DM, those with IRDM presenting with NSTEMI had an increased mortality than those with NIRDM.
    No preview · Article · Jul 2014 · The American Journal of Cardiology
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective: Type 2 diabetes mellitus is a clear prognostic marker for increased cardiovascular morbidity and mortality after acute myocardial infarction (AMI). We compared diabetes patients based on therapy used (no pharmacotherapy, those prescribed oral antihyperglycemic agents and those prescribed insulin) on the composite risk of recurrent AMI, congestive heart failure and mortality among elderly patients with AMI. Methods: Using administrative data, we identified patients, aged 65 years and older, with an incident AMI hospitalization in British Columbia and the Calgary Health Region between April 1, 1995, and March 31, 2002, for a retrospective cohort study. Cox proportional hazard models were constructed to compare time to reach the composite outcome in the treatment groups. Results: Among 22 499 patients with AMI, 5158 patients had diabetes. Women comprised 43.2% of the diabetes cohort. For the composite outcome, there was a stepwise increase in the occurrence based on medication use: no diabetes (23.55 events per 100 person-years); diabetes but no treatment (31.70 per 100 person-years); oral agents only (36.34 per 100 person-years) and insulin therapy (49.43 per 100 person-years). After adjustment, relative to patients without diabetes, no treatment (hazard ratio 1.37, 95% confidence interval, 1.22 to 1.53), oral agents only (hazard ratio 1.43, 95% confidence interval, 1.31 to 1.56) and insulin therapy (hazard ratio 1.65, 95% confidence interval, 1.48 to 1.84) were all associated with an increased risk of the outcome developing. Conclusions: Diabetes conferred a significant risk increase in a combination of cardiovascular events after AMI. The risk existed even for diabetes patients not prescribed therapy and showed a progressive trend as the intensity of treatment advanced toward insulin.
    No preview · Article · Sep 2014 · Canadian Journal of Diabetes